Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204736 | 0.89 | CA12 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1096255 | 0.88 | HTT (0.58) | CA12CA1CA2CA7CA9 | |
| Methyl 2,6-Dimethoxybenzoate SCHEMBL2095636 | 0.88 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL6932941 | 0.87 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1666445 | 0.86 | CA1 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11282176 | 0.84 | KDM4E (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9951884 | 0.83 | NPC1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27959009 | 0.83 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18315876 | 0.82 | TSHR (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21543727 | 0.82 | HCRTR1 (0.51) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007403-B1 | 5,12-DIHYDROXY-1,2,3,4,6,11-HEXAHYDRO-2,6,11-TRIOXONAPHTHACENES AND THEIR SYNTHESIS | THE UNIVERSITY OF KANSAS (US) | 1982-11-24 | — | — | EP | claimed |
| EP-0043435-A1 | Intermediate products occurring in anthracycline synthesis | THE UNIVERSITY OF KANSAS (US) | 1982-01-13 | — | — | EP | claimed |
| US-4244880-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1981-01-13 | — | — | US | claimed |
| EP-0007403-A1 | 5,12-dihydroxy-1,2,3,4,6,11-hexahydro-2,6,11-trioxonaphthacenes and their synthesis | THE UNIVERSITY OF KANSAS (US) | 1980-02-06 | — | — | EP | claimed |
| CN-116783179-A | Compounds and methods for targeted degradation of androgen receptor proteins | 阿尔维纳斯运营股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111892577-B | Compounds and methods for androgen receptor targeted degradation | 阿尔维纳斯运营股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2023-04-20 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-4374979-A | Regiospecific synthesis of anthracyclinone compounds such as daunomycinone | THE UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0007403-B1 | 5,12-DIHYDROXY-1,2,3,4,6,11-HEXAHYDRO-2,6,11-TRIOXONAPHTHACENES AND THEIR SYNTHESIS | THE UNIVERSITY OF KANSAS (US) | 1982-11-24 | — | — | EP | disclosed |
| EP-0063945-A1 | Process for the regiospecific synthesis of anthracyclinone compounds such as daunomycinone | THE UNIVERSITY OF KANSAS (US) | 1982-11-03 | — | — | EP | disclosed |
| EP-0043435-A1 | Intermediate products occurring in anthracycline synthesis | THE UNIVERSITY OF KANSAS (US) | 1982-01-13 | — | — | EP | disclosed |
| US-4244880-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1981-01-13 | — | — | US | disclosed |
| EP-0007403-A1 | 5,12-dihydroxy-1,2,3,4,6,11-hexahydro-2,6,11-trioxonaphthacenes and their synthesis | THE UNIVERSITY OF KANSAS (US) | 1980-02-06 | — | — | EP | disclosed |
| US-3944560-A | BRONCHODILATOR | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | CYP2B6, TYR, CYP2D6 | CA12 1684/4885CA1 1543/4885CA2 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.